Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
TG Therapeutics, Inc.
This Phase I clinical trial aims to evaluate the safety of the investigational drug TG-1701 both as a single-agent and in combination with other investigational drugs, specifically ublituximab and umbralisib. As per protocol v6.0, combination therapy (TG-1701 + Ublituximab + Umbralisib) will be discontinued and the participants from Arm 1 and 2 will be transitioned to the long-term extension period to receive TG-1701 monotherapy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Relapsed or refractory histologically confirmed B-cell lymphoma or CLL
Eastern Cooperative Oncology Group (ECOG) score of 0 to 2
Adequate organ function
You may not be if
Prior therapy with a BTK inhibitor (ibrutinib, acalabrutinib, other)
Any major surgery, chemotherapy or immunotherapy within the last 21 days
Known hepatitis B virus, hepatitis C virus or HIV infection